Zydus JV to set up USD 20 million pharma plant in Sri Lanka

Capex & Operations View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹1124.70

prior close

₹1127.50

announcement price

In-mkt

timing

Nifty 100market+1.3%+0.1% vs market

Pharmaceuticals peers, median of 172sector-0.6%+2.0% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty 100 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.1

15m

-0.1

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4+1.3+0.1-0.6+2.0

Next day

-0.2+1.9-2.0-0.7+0.5

-1.0+0.9-1.8-1.9+1.0

-0.7+0.3-1.0-3.5+2.9

+0.9-0.2+1.1-4.4+5.3

+0.4-0.9+1.4-6.1+6.5

+4.3+0.0+4.3-2.9+7.1

15d

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Sunshine Lifesciences, a joint venture between Zydus Lifesciences and Sunshine Healthcare, has signed an agreement with Sri Lanka's Board of Investment to set up a pharmaceutical manufacturing plant in the BOI zone at Horana, Sri Lanka. The project involves a phased investment of over USD 20 million on a four-acre site, with commercial operations expected to start in 2028 subject to approvals. The first phase will manufacture oral solid dosage forms for the Sri Lankan market.

Likely market impact

Strengthens Zydus's international presence, though commercial output is about two years away, limiting near-term earnings impact.